Five studies in this review assessed whether medications targeting the NO-sGC-cGMP pathway could improve spirometry and diffusion capacity parameters among COPD patients with PH (Li et al., 2021; Vitulo et al., 2017; Ghofrani et al., 2015; Pichl et al., 2019; Vonbank et al., 2003). The gene discussed is SGCB; the disease is chronic obstructive pulmonary disease.